Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown

V2, Crosslink

🧫

Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-lrrk2-aa

🧫 Experiment Protocol Validationproposed

SUMMARY

# Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown ## Background and Rationale Parkinson's disease (PD) is characterized by progressive neurodegeneration, with mutations in the LRRK2 gene representing one of the most common genetic causes. The G2019S mutation in LRRK2 leads to increased kinase activity and neuronal toxicity, making LRRK2 an attractive therapeutic target for gene therapy approaches. Adeno-associated virus (AAV) vectors have emerged as promising delivery systems for neuro

METHODOLOGY NOTES

Phase 1 (Weeks 0-1): Genotype confirmation of LRRK2-G2019S transgenic mice (n=60, 8-10 weeks old). Randomize into 5 groups (n=12 each): AAV9-shLRRK2, AAV-PHP.eB-shLRRK2, AAV-DJ-shLRRK2, AAV2/5-shLRRK2, and control AAV-scrambled shRNA. Phase 2 (Week 2): Perform stereotactic injections of AAV vectors (2×10^12 vg/ml, 2μl per injection site) bilaterally into substantia nigra and striatum under isoflurane anesthesia. Monitor post-surgical recovery for 7 days. Phase 3 (Weeks 3-8): Conduct weekly behavioral assessments including rotarod performance (accelerating 4-40 rpm over 5 minutes), cylinder test for forelimb asymmetry, and open field locomotor activity. Phase 4 (Week 6): Sacrifice subset of mice (n=4 per group) for early timepoint analysis. Collect brain tissue for biodistribution analysis via qPCR using serotype-specific primers. Phase 5 (Week 9): Perform final behavioral testing battery. Sacrifice remaining mice and harvest brains. Process tissues for Western blotting (LRRK2, tyrosine

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.902069Z'}
summary	# Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown ## Background and Rationale Parkinson's disease (PD) is characterized by progressive neurodegeneration, with mutations in the LRRK2 gene rep
entities	{'genes': ['AAV'], 'diseases': ["Parkinson's Disease"]}
model_system	mouse
_schema_version	1
experiment_type	validation
primary_outcome	Validate Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
methodology_notes	Phase 1 (Weeks 0-1): Genotype confirmation of LRRK2-G2019S transgenic mice (n=60, 8-10 weeks old). Randomize into 5 groups (n=12 each): AAV9-shLRRK2, AAV-PHP.eB-shLRRK2, AAV-DJ-shLRRK2, AAV2/5-shLRRK2
replication_status	replicated
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.902074', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

696

Outgoing

645

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown

derives from (16)

supports (94)

💬 Discussion